Back to Browse Journals » Core Evidence » Volume 4

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis

Authors Jonathan Kay, Mahboob U Rahman

Published 23 July 2009 Volume 2009:4 Pages 159—170


Jonathan Kay1, Mahboob U Rahman2,3

1Division of Rheumatology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA; 2Centocor Research and Development, inc., Malvern, PA, USA; 3University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Introduction: The introduction of tumor necrosis factor-α (TNF-α) inhibitors represented a significant advance in the management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. Although three TNF-α inhibitors have been approved for the treatment of RA by the US Food and Drug Administration (FDA) and the European Medicinal Products Evaluation Agency (EMEA), not all patients achieve a satisfactory clinical improvement with these therapeutic agents. The mode of administration of these medications is inconvenient for some patients.

Aims: Golimumab is a novel anti-TNF-α monoclonal antibody that is in clinical development for the treatment of RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), either as a first-line biologic therapy or an alternative after other TNF-α inhibitors have been discontinued. This review summarizes the development of, and clinical evidence achieved with, golimumab.

Evidence review: Golimumab has demonstrated significant efficacy in randomized, double-blind, placebo-controlled trials when administered subcutaneously once every four weeks. It has been generally well tolerated in clinical trials and demonstrates a safety profile comparable with currently available TNF-α inhibitors.

Outcomes summary: Golimumab has been confirmed to be an effective treatment for patients with RA, PsA, and AS in phase III clinical trials as evaluated by traditional measures of disease activity, such as signs and symptoms, as well as measures of physical function, patient reported outcomes, and health economic measures. The efficacy and safety profile of golimumab in RA, PsA, and AS appears to be similar to other anti-TNF agents. However, golimumab has the potential advantage of once monthly subcutaneous administration and the possibility of both subcutaneous and intravenous administration.

Keywords: golimumab, TNF-α inhibitors, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification]

Weiss GJ, Khemka V

OncoTargets and Therapy 2015, 8:2643-2644

Published Date: 18 September 2015

Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy

Zhuang B, Li Z, Pang J, Li W, Huang P, Wang J, Zhou Y, Lin Q, Zhou Q, Ye X, Ye H, Liu Y, Zhang LM, Chen R

International Journal of Nanomedicine 2015, 10:939-947

Published Date: 29 January 2015

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Altered diastolic function and aortic stiffness in Alzheimer’s disease

Çalık AN, Özcan KS, Yüksel G, Güngör B, Aruğarslan E, Varlibas F, Ekmekci A, Osmonov D, Tatlısu MA, Karaca M, Bolca O, Erdinler I

Clinical Interventions in Aging 2014, 9:1115-1121

Published Date: 16 July 2014

Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy

Cruz-Bustos T, González-González G, Morales-Sanfrutos J, Megí­a-Fernández A, Santoyo-González F, Osuna A

International Journal of Nanomedicine 2012, 7:5941-5956

Published Date: 3 December 2012

Controlled-release formulation of antihistamine based on cetirizine zinc-layered hydroxide nanocomposites and its effect on histamine release from basophilic leukemia (RBL-2H3) cells

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Zainal Z, Hakim MN

International Journal of Nanomedicine 2012, 7:3351-3363

Published Date: 3 July 2012

Comparing the effects of nano-sized sugarcane fiber with cellulose and psyllium on hepatic cellular signaling in mice

Wang ZQ, Yu Y, Zhang XH, Floyd ZE, Boudreau A, Lian K, Cefalu WT

International Journal of Nanomedicine 2012, 7:2999-3012

Published Date: 18 June 2012

RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating αvβ3 expression

Xu WC, Luo T, Li P, Zhou CQ, Cui DX, Pang B, Ren QS, Fu S

International Journal of Nanomedicine 2012, 7:915-924

Published Date: 27 February 2012

Increased fibroblast functionality on CNN2-loaded titania nanotubes

Wei HB, Wu SY, Feng ZH, Zhou W, Dong Y, Wu GF, Bai SZ, Zhao YM

International Journal of Nanomedicine 2012, 7:1091-1100

Published Date: 23 February 2012